Studies discussed in this Perspectiveon dual MDM-2–TSPO inhibitors,86 dual HDAC1–LSD inhibitors,87 dualPDK1–aurora kinase inhibitors,88 dual RGD integrin–MDM protein inhibitors,89 and others90−92 are expected to pave the way for the initiation ofsimilar programs to expand the size of the anti-GBM pipeline. The gene discussed is MDM2; the disease is glioblastoma.